Mon, May 23, 2022

Quality Improvement of Diagnostic Tests for Chronic Kidney Disease

 | Post date: 2019/04/4 | 
Quality Improvement of Diagnostic Tests for Chronic Kidney Disease

Recent Publications
  1. Quality management in biochemistry: A practical approach, Aeeizh, Tehran, 2017.
  2. Summary of management in biochemistry; Aeeizh, Tehran, 2018.
  3. External Quality Assessment of Glycohemoglobin in Iran: Comparison of Five Different Commercial Methods with two different total allowable errors. J Med Biochem 37; 1-9, 2018.
  4. Evaluation of the performance of common serum and urine creatinine measuring kits: Is the results of these methods clinically useful. Journal of Islamic Azad University. Tehran medical sciences branch 1397: 28 (2). 162-168.

Chronic kidney disease (CKD) is an important public health problem and is a risk factor for cardiovascular diseases. CKD is usually asymptomatic until later stages and routine laboratory tests, including serum creatinine and urine protein, are not clinically sensitive enough to detect early stages of CKD. Using creatinine clearance is a suitable approach for detecting early stages, but it has different challenges. In addition, the clinical usefulness of these laboratory tests results is affected by analytical sensitivity and specificity, biological variation, need to collect 24 hours urine, diet, and activity. As early detection of CKD is necessary for preventing the progression of kidney disease to kidney failure, it is essential to standardize these laboratory tests in pre-analytical, analytical, and post-analytical stages, and using more sensitive and specific tests. For more than ten years, it is recommended to use estimated glomerular filtration rate (eGFR) as a sensitive marker for screening early stages of CKD. Different formulas have been introduced for estimation of GFR according to serum creatinine, race, sex, age, and body weight, each of which has its advantages and disadvantages.
In this panel, we will discuss about challenges in detection, diagnosis and monitoring of CKD in pediatrics and adults according to laboratory tests, problems of standardization of creatinine and urine albumin measuring methods, and limitations of different formulas for estimating GFR, and also introduce strategies for quality improving of these tests.



Dr. Reza Mohammadi, Ph.D

1- Doctor of clinical laboratory sciences and Ph.D of clinical biochemistry from Tehran medical university.
2- Assistant Professor and chief of the biochemistry department of Islamic Azad University. Tehran medical sciences branch.
3- Secretary of the board of biochemistry in external quality assessment program (EQAP).


View: 703 Time(s)   |   Print: 307 Time(s)   |   Email: 0 Time(s)   |   0 Comment(s)